ImmuCell Co. (NASDAQ:ICCC) Short Interest Update

ImmuCell Co. (NASDAQ:ICCC) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 11,700 shares, a growth of 37.6% from the September 15th total of 8,500 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average trading volume of 38,800 shares, the short-interest ratio is currently 0.3 days.

ImmuCell Trading Up 1.7 %

Shares of ImmuCell stock traded up $0.06 during trading on Tuesday, hitting $3.63. The company’s stock had a trading volume of 20,954 shares, compared to its average volume of 19,359. The stock has a market cap of $28.36 million, a price-to-earnings ratio of -7.00 and a beta of 0.56. ImmuCell has a 52 week low of $3.34 and a 52 week high of $5.59. The stock has a 50-day moving average price of $3.70 and a two-hundred day moving average price of $4.30. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.37 and a quick ratio of 0.77.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.20) EPS for the quarter. ImmuCell had a negative net margin of 17.44% and a negative return on equity of 16.35%. The company had revenue of $5.47 million during the quarter.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.